Evidence map›Paper›PMID 36250098›Full record

ArticleFrontiers in medicine2022

Untargeted plasma metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of coronavirus disease 19.

Céline Occelli, Jean-Marie Guigonis, Sabine Lindenthal, Alexandre Cagnard, Fanny Graslin, Vesna Brglez, Barbara Seitz-Polski, Jean Dellamonica, Jacques Levraut, Thierry Pourcher

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts.Metabolomics : Official journal of the Metabolomic Society · 2026
    Review
  2. Review
  3. N-Lactoyl Amino Acids: Emerging Biomarkers in Metabolism and Disease.Diabetes/metabolism research and reviews · 2025
    Review
  4. Assessing metal-induced glycation in French fries.Metallomics : integrated biometal science · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Céline OccelliTransporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
Jean-Marie GuigonisTransporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
Sabine LindenthalTransporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
Alexandre CagnardTransporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
Fanny GraslinTransporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
Vesna BrglezUnité de Recherche Clinique Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
Barbara Seitz-PolskiSchool of Medicine, Université Côte d'Azur, Nice, France.
Jean DellamonicaSchool of Medicine, Université Côte d'Azur, Nice, France.
Jacques LevrautDepartment of Emergency, University Hospital, Nice, France.
Thierry PourcherTransporter in Imaging and Radiotherapy in Oncology Laboratory (TIRO), Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Frederic Joliot, Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA), Université Côte d'Azur, School of Medicine, Nice, France.
Centre Hospitalier Universitaire de Nice · FRInstitut des Sciences du Vivant Frédéric Joliot · FRObservatoire de la Côte d’Azur · FRUniversité Côte d'Azur · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRDirection de la Recherche Fondamentale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The COVID-19 pandemic has been a serious worldwide public health crisis since 2020 and is still challenging healthcare systems. New tools for the prognosis and diagnosis of COVID-19 patients remain important issues. Design: Here, we studied the metabolome of plasma samples of COVID-19 patients for the identification of prognosis biomarkers. Patients: Plasma samples of eighty-six SARS-CoV-2-infected subjects and 24 healthy controls were collected during the first peak of the COVID-19 pandemic in France in 2020. Main results: Plasma metabolome fingerprinting allowed the successful discrimination of healthy controls, mild SARS-CoV-2 subjects, and moderate and severe COVID-19 patients at hospital admission. We found a strong effect of SARS-CoV-2 infection on the plasma metabolome in mild cases. Our results revealed that plasma lipids and alterations in their saturation level are important biomarkers for the detection of the infection. We also identified deoxy-fructosyl-amino acids as new putative plasma biomarkers for SARS-CoV-2 infection and COVID-19 severity. Finally, our results highlight a key role for plasma levels of tryptophan and kynurenine in the symptoms of COVID-19 patients. Conclusion: Our results showed that plasma metabolome profiling is an efficient tool for the diagnosis and prognosis of SARS-CoV-2 infection.

Indexed as

biomarkersCOVID-19diagnosticmetabolomics (OMICS)prognostic

Identifiers

PMID36250098
PMCPMC9556858
OpenAlexW4298004513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.